anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a method for preparing a drug for treating multiple epiphyseal dysplasia. The drug is applied to the treatment of multiple epiphyseal dysplasia. The drug is characterized by being prepared from the following raw pharmaceutical materials in proportioning ratio by weight: litchi chinensis Sonn., bombax malabaricum peel, poriacocos (Schw.) Wolf, citrus reticulata Blanco, aeschynomene indica L., trachelospermum jasminoides (Lindl.) Lem., radix puerariae, paris polyphylla Sm., luffa cylindrica (L.) Roem., murraya jasminorage, hordeum vulgare L. and setaria italica (L.) Beauv.. The method comprises the following steps of: (1) extracting volatile oil from coarse powder of radix puerariae, bombax malabaricum peel and aeschynomene indica L. for later use; (2) crushing setaria italica (L.) Beauv. into fine powder for later use; (3) carrying out water extraction and alcohol precipitation on litchi chinensis Sonn., poriacocos (Schw.) Wolf, citrus reticulata Blanco, trachelospermum jasminoides (Lindl.) Lem., luffa cylindrica (L.) Roem., paris polyphylla Sm., murraya jasminorage and hordeum vulgare L., and drying so as to obtain a preliminary material; and (4) spraying the volatile oil into the preliminary material, adding the fine powder of setaria italica (L.) Beauv., uniformly mixing, sieving by using a 60-mesh sieve, and encapsulating. Proved by clinical trials, the drug prepared by the method has the characteristics of good treatment effect and high safety in the treatment of multiple epiphyseal dysplasia, so that the method is worthy of clinical application and popularization.
The present invention provides a method for introducing nucleic acids into cells. The method involves exposing the cells to a compound having formula (1), in which w is a nucleic acid, x is a peptide or amino acid, y is a linker having a chain length equivalent to 1 to 20 carbon atoms or is absent, R 4  is H ir CH 2  O--R 3  ; and R 1 , R 2  and R 3  are the same or different and are either hydrogen, methyl, ethyl, hydroxyl or an acyl group derived from a fatty acid having a carbon chain of 3 to 24 carbon atoms saturated or unsaturated, with the proviso that at least one of R 1 , R 2  and R 3  is an acyl group derived from a fatty acid, or to a compound having the formula (2): w . . . xyNHCH 2  CH 2  OR 5 , in which w is a nucleic acid, x is a peptide or amino acid, y is a linker having a chain length equivalent to 1 to 20 carbon atoms or absent, R 5  is an acyl group derived from a fatty acid having a carbon chain of 3 to 24 carbon atoms saturated or unsaturated. The invention also relates to these compounds. ##STR1##
PURPOSE: To obtain the subject formulation containing a specific stabilizer and capable of preserving in a liquid state in keeping a biological activity for a long period of time and having safety without freeze-drying a human blood coagulating XIII-th factor produced by a gene recombinant technique. CONSTITUTION: This formulation contains at least one species of galactose, sucrose, sorbitol, glutamate, aspartate and histidine as a stabilizer. As the glutamate or the asparate, its alkali (alkaline earth) metal salt is preferable. The galactose, sucrose or sorbitol is preferably used in a concentration of 10-20w/v% and the amino acid is preferably used in a concentration of 0.5-2w/v%. The XIII-th factor is preferably used in a concentration of 60-200 unit/ml. The objective formulation is preferably adjusted to pH7-8. Furthermore, the formulation is preferably preserved at about 4 deg.C.
Notalgia paresthetica is a common sensory neuropathy, affecting mainly the interscapular area especially the T2-T6 dermatomes. The characteristic symptom is pruritus on the upper back. It is occasionally accompanied by pain, paresthesia, hyperesthesia and a well circumscribed hyperpigmentation of the affected area. The correlation of notalgia paresthetica localization with corresponding degenerative changes in the spine suggest that spinal nerve impingement may be a contributing cause. Topical treatments such as corticosteroids, menthol, capsaicine and pramoxine are usually not very effective. Patients are very affected in their daily activities by this chronic condition and usually disappointed by the current available treatments.

A recent publication reports success in treating 2 patients with notalgia paresthetica with botulinum toxin A. In both cases a complete response for pruritus was noted. The major limitations of this publication are the small number of cases (two) and the fact that there was no control. The mechanism of action of botulinum toxin A in nostalgia paresthetica has not been investigated.

However the beneficial effects of botulinum toxin A on other diseases causing pruritus and pain has previously been reported. Botulinum toxin A has been shown to prevent the release of substance P, a well known mediator involved in pain and itch, and this may explain its efficacy in pruritic diseases. This proposal plans to study the efficacy and safety of botulinum toxin A (Xeomin) for the treatment of notalgia paresthetica in a randomized placebo controlled trial. Botulinum toxin A prevents the release of neuromediators such as acetylcholine. Botulinum toxin A has been used for many years to treat various disorders including blepharospasm, spasmodic torticollis, post stroke spasticity of the upper limbs, strabismus, palmar and axillary hyperhidrosis and wrinkles. This study will use Xeomin, a purified botulinum clostridium neurotoxin A that has recently been approved by Health Canada. Xeomin is currently approved for the treatment of blepharospasm, spasmodic torticollis and post stroke spasticity of the upper limbs.

A recent publication reported success in treating two patients with notalgia paresthetica with botulinum toxin A. In both cases a complete response of pruritus was noted. One patient was still symptom free after 18 months while the other patient had a mild resurgence of pruritus at 18 months. The major limitations of this publication are the small number of cases (two) and the fact that there was no control. The current proposal plans to study the efficacy and safety of botulinum toxin A for the treatment of notalgia paresthetica in a randomized placebo controlled trial. In this study Xeomin will be reconstituted and used according to the approved Canadian Product Monograph.
BACKGROUND: Many risk factors have been associated with migraine progression, including insufficient and ineffective utilization of migraine medications; however, they have been inadequately explored. This has resulted in suboptimal usage of medications without effective altering of prescribing recommendations for patients, posing a risk for migraine chronification.
METHODS: Our aim is to conduct a comprehensive review of the available evidence regarding the underuse of migraine medications, both acute and preventive. The term "underuse" includes, but is not limited to: (1) ineffective use of appropriate and inappropriate medication; (2) underutilization; (3) inappropriate timing of usage; and (4) patient dissatisfaction with medication.
RESULTS: The underuse of both acute and preventive medications has been shown to contribute to the progression of migraine. In terms of acute medication, chronification occurs as a result of insufficient drug use, including failure of the prescriber to select the appropriate type based on pain intensity and disability, patients taking medication too late (more than 60 minutes after the onset or after central sensitization has occurred as evidenced by allodynia), and discontinuation because of lack of effect or intolerable side effects. The underlying cause of inadequate effectiveness of acute medication lies in its inability to halt the propagation of peripheral activation to central sensitization in a timely manner. For oral and injectable preventive migraine medications, insufficient efficacy and intolerable side effects have led to poor adherence and discontinuation with subsequent progression of migraine. The underlying pathophysiology here is rooted in the repetitive stimulation of afferent sensory pain fibers, followed by ascending brainstem pain pathways plus dysfunction of the endogenous descending brainstem pain inhibitory pathway. Although anti-calcitonin gene-related peptide (CGRP) medications partially address pain caused by the above factors, including decreased efficacy and tolerability from conventional therapy, some patients do not respond well to this treatment. Research suggests that initiating preventive anti-CGRP treatment at an early stage (during low frequency episodic migraine attacks) is more beneficial than commencing it during high frequency episodic attacks or when chronic migraine has begun.
CONCLUSIONS: The term "medication underuse" is underrecognized, but it holds significant importance. Optimal usage of acute care and preventive migraine medications could potentially prevent migraine chronification and improve the treatment of migraine attacks.
This study is a prospective, nonrandomized trial evaluating the efficacy of directed antimicrobial prophylaxis prior to transrectal ultrasound-guided prostate biopsy (TRUSP) compared with ciprofloxacin prophylaxis, the current standard of care. Northwestern University will be the lead site. After signing informed consent, study participants will complete a pre-biopsy questionnaire to record demographics and assess for known risk factors for infection and will have a rectal swab obtained. Patients whose swabs indicate colonization with ciprofloxacin-susceptible gram-negative bacteria (CS-GNB) will receive ciprofloxacin as pre-procedure prophylaxis and those whose swabs indicate colonization with ciprofloxacin-resistant gram-negative bacteria (CR-GNB) will receive pre-procedure antimicrobial prophylaxis based on study protocol.

All patients will be contacted by phone twice after their biopsies, at approximately 7 and 30 days, to detail post-procedure infectious complications including fever, urinary tract infection, bacteremia and sepsis. Subjects who experience infections will have additional information regarding the infectious complications and cost of therapy abstracted from their medical record. The TRUSP results will also be recorded. Bacterial isolates from the rectal swabs will be archived.
FIELD: chemical-pharmaceutical industry. SUBSTANCE: therapeutic combination involves calcium in elemental form and at least one vitamin D as an associated active component. It has also at least one dry and moisture binding agent (synergetic amount) with at least one vehicle, at least one binding agent and at least one binding agent being at least one of indicated vehicles and indicated binding agents is a sweetening agent. Ratio of calcium in elemental form to vitamin D expressed as mg of elemental calcium per international unit (IU) of vitamin D is mainly 1-1.5 but, preferably, is 1.2-1.3. Invention provides maintenance of absolute and relative doses of calcium and vitamin D and correct treatment carrying out. EFFECT: enhanced effectiveness of combination. 16 cl
In this study, all participants have normal pulmonary arterial pressure at rest and elevated pulmonary arterial pressure during exercise. First, they were followed up for a year and were controlled after 1 year without specific therapy for pulmonary hypertension. Then Bosentan was introduced. A second control showing the effects of the therapy was done after 6 months. The changes in the "therapy period" can be compared with the changes in the "follow up period".
PURPOSE:The titled pharmaceutical containing a specific amino acid added thereto. CONSTITUTION:A stable active type vitamin D3 pharmaceutical obtained by adding an amino acid, e.g. neutral amino acid such as alanine, valine, proline, phenylalanine, tryptophan, leucine, isoleucine, glycine or serine, or basic amino acid such as lysine, arginine or histidine, except amino acids ahving sulfur atom or acid amide group in the structure and salts of acid amino acids and basic amino acids to active type vitamin D3, e.g. 1alpha-hydroxyvitamin D3, 1alpha,24- dihydroxyvitamin D3 or 1alpha,24,25-trihydroxyvitamin D3. The amount of the amino acid to be added may be an equal amount -100,000 times based on the active type vitamin D3 and particularly preferably 10-500 times based on the active type vitamin D3 for liquid pharmaceutical and 5,000-50,000 times based on the active type vitamin D3 for solid pharmaceutical. An injection, syrup, emul sion, etc., may be cited as the dosage form.
BACKGROUND: Obesity is as an important risk factor for chronic diseases. Metabolically healthy obesity (MHO) is considered a benign state. The association between metabolic health and obesity categories and cancer risk remains unclear. This study aimed to investigate the relationship between metabolic health status combined with obesity phenotypes and the risk of cancer.
METHODS: Data from 91,834 participants in the Kailuan cohort were analyzed, excluding individuals with a body mass index (BMI) < 18.5 kg/m² and those with a history of cancer. Obesity phenotypes were classified based on BMI and waist circumference (WC) combined with metabolic health status, resulting in six phenotypes. Cox proportional hazard regression models were used to assess the association between metabolic health and obesity phenotypes with cancer risk and all-cause mortality.
RESULTS: The prevalence of metabolically healthy obesity and metabolically unhealthy obesity defined by BMI was 6.86% and 12.18%, while that defined by WC was 20.79% and 25.76%, respectively. Compared to metabolically healthy participants, individuals with an unhealthy metabolic status had a significantly higher risk of cancer (HR, 1.09; 95% CI, 1.03-1.15; p=0.004). The hazard ratios for cancer were 1.19, 1.23, 1.20, and 1.55 for individuals with one, two, three, and four metabolic disorders, respectively. Among those classified as metabolically unhealthy, both overweight and obesity were associated with a protective effect on cancer risk (HR, 0.88; 95% CI, 0.80-0.96; p=0.006 for overweight; HR, 0.87; 95% CI, 0.78-0.97; p=0.010 for obesity). However, abdominal obesity significantly increased cancer risk in both metabolically healthy and unhealthy participants. In subgroup analysis, simple obesity showed a protective trend against cancer in those with respiratory cancers, while abdominal obesity consistently posed a risk for various cancer types.
CONCLUSION: Metabolically unhealthy status and abdominal obesity are risk factors for cancer and all-cause mortality, whereas simple obesity offers protective effects against cancer and all-cause mortality in metabolically unhealthy individuals. These findings suggest that maintaining metabolic health and reducing the metabolic risks associated with abdominal obesity should be key targets for cancer prevention.
Matrix metalloproteinases (MMPs) degrade extracellular matrix proteins and are important for placenta formation during early pregnancy. Recurrent pregnancy loss (RPL) is associated with abnormalities in endometrial extracellular matrix remodeling. This study aimed to elucidate the roles of MMP2 and MMP9 in RPL pathogenesis. In total, 295 women with a history of RPL and 101 controls were included in this genetic study. Genotype analysis was performed using polymerase chain reaction (PCR) restriction fragment length polymorphisms. For proteolytic analysis, decidua and villi were collected from 10 RPL-miscarried women with normal fetal chromosomes (NC) and 19 women with fetal chromosome aberrations (AC). The expression of MMP2 and MMP9 in the decidua and villi was measured by IHC and ELISA. All samples were collected after obtaining informed consent. There were no statistically significant differences in MMP2-735 C/T and MMP9-1562 C/T frequencies between women with RPL and the controls. There was no significant difference in MMP2 expression levels in the villi; however, MMP9 expression was significantly higher in normal fetal chromosomes. In the decidua, the expression of MMP2 in the NC group was significantly lower, and MMP9 in the NC group was significantly higher than in the AC group. Although no differences in MMP2-735 C/T and MMP9-1562 C/T gene polymorphisms were observed in the present study, it is suggested that differences at the protein level are involved in the pathogenesis of RPL since MMP expression is not only regulated by genes but also by local inflammation and various inductive signals.
The invention belongs to the technical field of drug targets and in particular relates to application of a small molecular lead compound with inhibiting effect on mycobacterium tuberculosis. The small molecular compound is a pyrazol compound, with a chemical name being 2-({[1-(4-methylphenyl)-1H-pyrazol-4-yl]methyl}amino)ethanol. The compound has the advantages of small molecular weight, simple structure, good permeability and the like and can effectively inhibit growth of mycobacterium tuberculosis. Mycobacterium tuberculosis is a pathogenic bacterium of tuberculosis, so the small molecular compound has the potential of treating tuberculosis and is expected to be developed into a new antituberculosis drug. Therefore, the small molecular compound can be developed as a new antituberculosis drug and provides a new approach for treatment and cure of tuberculosis. The invention also relates to application of preparations containing the small molecular inhibitor to preparation of antituberculosis drugs.
A case information optimization and acquisition method for a medical system based on a cloud platform relates to the field of information memory and safety. The medical information of all patients of a plurality of hospitals are stored in a database of a cloud server and aggregated, so that under the condition that the patients authorize, any hospital can use a client terminal to access the database of the cloud server and obtain the medical information of the patients. The medical information of all the hospitals is uploaded and aggregated by grades and finally aggregated into a cloud main database. If a patient sees a doctor at the same hospital for multiple times, the patient only needs to fill the personal basic information at the first time, and for the rest times, the patient can use a patient ID card uniquely identifying the identity of the patient. The time that the patient registers, queues up and fills the personal basic information is shortened, and the screening step of screening stored information is also reduced. The information exchange of all the hospitals and all departments is realized, and the 'information isolated island' problem is solved.
OBJECTIVES: Surgery for congenital malformation of the hand is complex and protocols are not available. Simulation could help optimize results. The objective of the present study was to design, produce and assess a 3D-printed anatomical support, to improve success in rare and complex surgeries of the hand.
MATERIAL AND METHODS: We acquired MRI imaging of the right hand of a 30 year-old subject, then analyzed and split the various skin layers for segmentation. Thus we created the prototype of a healthy hand, using 3D multi-material and silicone printing devices, and drew up a printing protocol suitable for all patients. We printed a base comprising bones, muscles and tendons, with a multi-material 3D printer, then used a 3D silicone printer for skin and subcutaneous fatty cell tissues in a glove-like shape. To evaluate the characteristics of the prototype, we performed a series of dissections on the synthetic hand and on a cadaveric hand in the anatomy lab, comparing realism, ease of handling and the final result of the two supports, and evaluated their respective advantages in surgical and training contexts. A grading form was given to each surgeon to establish a global score.
RESULTS: This evaluation highlighted the positive and negative features of the model. The model avoided intrinsic problems of cadavers, such as muscle rigidity or tissue fragility and atrophy, and enables the anatomy of a specific patient to be rigorously respected. On the other hand, vascular and nervous networks, with their potential anatomical variants, are lacking. This preliminary phase highlighted the advantages and inconveniences of the prototype, to optimize the design and printing of future models. It is an indispensable prerequisite before performing studies in eligible pediatric patients with congenital hand malformation.
CONCLUSION: The validation of 3D-printed anatomical model of a human hand opens a large field of applications in the area of preoperative surgical planning. The postoperative esthetic and functional benefit of such pre-intervention supports in complex surgery needs assessing.
Polydopamine nanomaterials have emerged as one of the most popular organic materials for the management of oxidative stress-mediated inflammatory diseases. However, their current anti-inflammatory ability is still unsatisfactory because of limited phenolic hydroxyl groups, and oxidation reaction-medicated reactive oxygen and nitrogen species (RONS) scavenging. Herein, via fusing dimension engineering and surface charge engineering, 2D cationic polydopamine nanosheets (PDA NSs) capable of scavenging multiple danger signals to enhance anti-inflammatory capability are reported. Compared with conventional spherical polydopamine nanoparticles, 2D PDA NSs exhibit three- to fourfold enhancement in RONS scavenging capability, which should be attributed to high specific surface area and abundant phenol groups of 2D ultrathin structure. To further enhance the anti-inflammatory ability, polylysine molecules are absorbed on the surface of PDA NSs to endow the scavenging capability of cell-free DNA (cfDNA), another typical inflammatory factor to exacerbate the pathogenesis of inflammation. Molecular mechanisms reveal that cationic PDA NSs can concurrently activate Keap1-Nrf2 and block TLR9 signaling pathway, achieving synergistical inflammation inhibition. As a proof of concept, cationic PDA NSs with RONS and cfDNA dual-scavenging capability effectively alleviate the inflammatory bowel disease in both delayed and prophylactic models, much better than the clinical drug 5-aminosalicylic acid.
547,913. Naphthoquinone derivatives. ABBOT LABORATORIES. March 21, 1941, No. 3878. Convention date, March 25, 1940. [Class 2 (iii)] Anti-haemorrhagic compounds suitable for oral or parenteral administration are prepared by reacting 2-methyl-1:4-naphthoquinone with a water soluble bisulphite salt. Suitable bisulphite salts mentioned include those of an alkali metal, an alkaline earth metal, an amine or an alkanolamine. The compounds are stated to possess strong vitamin K activity. In examples (1) Equi-molecular amounts of 2- methyl-1:4-naphthoquinone and sodium bisulphite are mixed in aqueous solution ; (2) 2- methyl-1:4-naphthoquinone is mixed in aqueous solution with two molecules of potassium bisulphite. The alkali salts in the above examples may be replaced by ammonium salts and amine salts. The amines mentioned include primary, secondary and tertiary alkyl and substituted alkyl amines.. Hydroxy substituted alkyl and aromatic amines may also be used together with cycloalkyl amines including cycloalkyl groups in which the nitrogen atom is included in a heterocyclic ring. The compounds of the invention are stated to be stable to sunlight.
Patients received oral feeding with an ordinary diet plus 400 mL/day (400 kcal/day) of the standard diet for 3-5 days before curative surgery for gastric adenocarcinoma or gastric GIST. On postoperative day 3, EN was initiated with 5% glucose in water at a rate of 20 mL/h. On postoperative day 4, patients received a semi-liquid diet plus 400 mL/day (400 kcal/day) of the interventional diet. From postoperative day 5-14 or to discharge whichever occurred first, 1200 mL/day (1200 kcal/day) of the standard diet was administered, and an oral soft diet was also administered if no postoperative complications developed and if oral feeding was not prohibited.